Tuesday, 27 October 2020

Odin (BioLargo/BKT Joint Venture) Headquarters Moving to Korea Water Cluster in Daegu, South Korea

Earlier this year, BioLargo announced the formation of a joint venture with BKT & Tomorrow Water to launch BioLargo’s patented odor and VOC control product CupriDyne Clean (www.cupridyne.com) into the Asian market under the brand name “Odin”. The new join venture was designed to manufacture and support distribution of the odor and VOC control products developed and sold by its subsidiary ONM Environmental, Inc. (www.onmenvironmental.com) in multiple countries throughout Asia, focusing initially on BKT’s established water and wastewater customer base.

BKT is a leading wastewater treatment solutions provider operating in the USA, South Korea, and Vietnam with a reputation for adopting innovative, environmentally sustainable technologies and practices. In the agreement between BioLargo and BKT, it was planned that the joint venture would eventually move its headquarters to the city of Daegu, which is a center for high-tech innovation in South Korea.

The BKT/BioLargo joint venture (Odin) is now officially moving its headquarters to the Korea Water Cluster in Daegu. The Korea Water Cluster is a newly opened water innovation hub in Daegu that provides significant business, scientific, engineering, human resources, and logistical assets to companies. Odin is set to be the first international joint venture headquartered at the Korea Water Cluster campus.

Water clusters and innovations groups exist all over the world, but the Korea Water Cluster is unique because of its significant physical footprint in Daegu, its substantial physical resources, and the funding it has received from the South Korean government. The Korea Water Cluster’s campus spans over 14 square kilometers, with state-of-the art testing facilities and business support centers.

Overview of Korea Water Cluster facilities (source: www.watercluster.or.kr


James Kim, COO of BKT, commented on the importance of the move to Daegu, “the Water Cluster will be a hub for R&D in the water  industry, and it will introduce innovative technologies in one place, providing opportunity for collaboration and cooperation among companies and ventures.”

He continued, “Korea Water Cluster will be a test bed and showcase for many innovative technologies not only for Korean clients but also many other clients in Asia. Odor is one of the major issues that wastewater treatment plants would like to remove, and it is becoming more important. By moving its headquarters to this Water Cluster, Odin will be naturally exposed to more clientele in Korea and also in Asia. BioLargo and Tomorrow Water signed an MOU with the City of Daegu at the WEFTEC last year, and the Mayor of Daegu promised strong support on market expansion in this region. Odin is the first foreign invested joint venture who moved into this cluster.”

Odin’s move to the Korea Water Cluster comes at a time when the joint venture is working to establish its manufacturing base for odor and VOC control products in South Korea. Not only will the move provide access for Odin to key opinion leaders in the water innovation industry in South Korea, but it will allow for significant business-to-business collaboration as the joint venture partners works to market Odin products in the region.

Wednesday, 21 October 2020

BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility

Westminster, CA – October 21, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US, owned by a global chemical company, that produces phenolic resins, antioxidants and related synthetic organic products. The contract is expected to execute with a series of milestones through mid-2021, with anticipated scope expanding the contract period to at least 24 months and over $500,000 in total revenue.

A Regenerative Thermal Oxidizer is a device that destroys unwanted organic air contaminants produced as a result of the phenolic resin production process. An RTO is a highly energy-efficient technology that uses waste heat to eliminate organic air contaminants, and is a crucial piece of equipment for this chemical plant.

The plant is preparing to shut down an existing, older RTO and re-route the exhaust treated by that RTO to a newer, much larger and more efficient RTO. This will result in significant energy efficiency and cost savings improvements to the facility. The work to reconfigure these RTO systems is not trivial, requiring substantial engineering and design work to ensure it proceeds safely and efficiently. BLEST has been contracted to conduct the initial engineering work to assess the feasibility of the RTO reconfiguration project. BLEST engineers have significant experience engineering and designing RTO systems, with some of its engineers having designed multiple RTO systems for the facility.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Thursday, 15 October 2020

Lorianne Shultz Awarded 2020 NWRI-BioLargo Graduate Fellowship

For many years, BioLargo has sponsored fellowships offered by the National Water Research Institute (NWRI) to graduate students in the US who focus on cutting-edge water research. This $5,000 fellowship recognizes students who research the technical and scientific aspects of advanced water and wastewater treatment.

This year, we are happy to announce that the NWRI-BioLargo Graduate Fellowship has been awarded to Lorianne Shultz, a PhD student at the University of Central Florida. Shultz’s research project, which she is completing in the laboratory of Dr. Titel Jurca, is called “Chlorine Stable Heterogeneous Catalysts for the Remediation of Stubborn Water Pollutants”.

Lorianne Shultz, NWRI-
BioLargo Fellowship winner

Lorianne explained to us the importance of her research, “Pharmaceuticals and personal care products are accumulating in our waterways at alarming rates; this is especially true with the world’s growing population. This issue can be remediated through heterogenous catalytic degradation of these pollutants, a methodology that I believe is commonly overlooked in the water-industry. I was thrilled to receive this fellowship as it helps validate the use of catalytic materials for water-remediation and these funds help me expand this field of research further. I am excited to be working in connection with BioLargo, a company so dedicated to this field and at the forefront of improvement for water treatment systems.”

Dennis P. Calvert, President & CEO of BioLargo, commented, “Shultz’s research goals align well with NWRI’s mission to protect and improve water management in the US, and they also align with BioLargo’s vision of seeking innovative new methods of addressing tough contaminants that threaten the health and safety of people around the world. We are thrilled to sponsor her work, and we are excited to learn from her research.”

NWRI is a 501c3 nonprofit that collaborates with water utilities, regulators, and researchers in innovative ways to help develop new, healthy sources of drinking water. To learn more about NWRI’s graduate fellowship program, go to the NWRI website: https://www.nwri-usa.org/fellowships.

Wednesday, 14 October 2020

Clyraguard Personal Protection Spray Now Available On Amazon.Com For Consumers Nationwide

BioLargo subsidiary Clyra Medical Technologies Joins Forces with Powerplay Retail to Ensure

Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses

Westminster, CA – October 14, 2020 – Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily decontaminates masks and face coverings, is now available at the Clyra Medical Store on Amazon.com. Clyraguard is manufactured by BioLargo’s subsidiary Clyra Medical Technologies, a med-tech company with deep experience fighting hospital-acquired infections with innovative technologies.

In addition, Clyra Medical announced a partnership with Powerplay Retail, an agency and distributor that has helped launch some of the best-known consumer products in the world, to roll-out Clyraguard to major retailers nationwide. Powerplay Retail brings to bear relationships with some of the world’s biggest online and in-store retailers, including more than 80 of the largest, most recognizable retailers in the United States.

BioLargo President & CEO Dennis Calvert commented, “We have assembled an exceptional team to execute a multi-phase roll out plan for Clyraguard. This Amazon launch, in partnership with Powerplay Retail, is another important step toward maximizing consumer access to this valuable product.”

“As we continue to battle this unprecedented pandemic, Clyraguard provides an embedded layer of iodine on one’s mask or face covering for additional protection against unwanted pathogens, including the SARS-CoV-2 virus, without having to remove your mask,” said Steve Harrison, CEO, Clyra Medical Technologies. “Until now, this hospital-grade disinfectant was available only to healthcare professionals. Making Clyraguard available on Amazon.com, as well as partnering with Powerplay Retail, ensures we can deliver a much-needed solution to consumers nationwide.”

Clyraguard has shown complete inactivation of SARS-CoV-2 (COVID-19), according to recent testing at University of Texas Medical Branch at Galveston, and is based on Clyra Medical’s original advanced wound care technology, which received 510(k) clearance from the Food and Drug Administration (FDA).  Clyraguard is a hospital-grade, FDA-registered disinfectant that is specifically indicated for PPE, like masks and face coverings.

“At Powerplay our goal is to help our retail partners find the right brands and the right technologies while weeding out the noise in this increasingly competitive marketspace,” said Tracy Thie, Principal, Co-Founder Powerplay Retail.  “As health and safety have become a core part of our daily lives, we have made it a point to help support our retail partners to bring the right health & wellness products to the masses. Our partnership with Clyra creates a great opportunity to bring Clyraguard to market at a time when people want and need this product.”

Clyraguard has been rigorously tested and proven to be safe and long-lasting, providing an extremely high 99.999% antimicrobial efficacy against viruses, bacteria and fungi.  Gentle and safe, its eco-friendly ingredients are mineral-based, alcohol-free, non-toxic, non-irritating and non-sensitizing.

Available in 4 oz. spray bottle, the personal protection spray is small enough for a purse or pocket yet contains two months of supply with typical usage, and for travelers, Clyraguard classifies under current TSA hand sanitizer exemptions. Clyraguard is now available to consumers online at www.clyramedical.com, the Clyra Medical Store on Amazon.com, and soon to be available at retailers nationwide.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies

Clyra Medical Technologies, is a subsidiary of BioLargo, Inc. (OTCQB:BLGO), a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver solutions in clean water and wastewater treatment, clean air and air quality control, and advanced antimicrobials for healthcare. 

About Powerplay Retail

Powerplay Retail is a privately held, Minnesota based company with offices in Bentonville, Arkansas, and Shenzhen China. With over 250 years of combined retail experience bringing brands like Beats by Dr. Dre and GoPro to consumers they continue to vet and identify new retail opportunities to best serve their brand and retail partners. For more information on Powerplay Retail, visit powerplayretail.com.

Contact

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Thursday, 8 October 2020

BioLargo Breaks Revenue Records in Third Quarter of 2020

Clyraguard manufacturing and distribution through national partners begins

Westminster, CA – October 8, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and full-service environmental engineering company, today provided highlights of its results and activities from the third quarter of 2020.

BioLargo President & CEO Dennis P. Calvert commented, “With our subsidiary Clyra Medical Technologies having successfully executed the first phase of the Clyraguard product launch, this quarter set new records for BioLargo, and we expect the next quarter to be even stronger for the company and Clyraguard. We have made a significant investment in building our supply chain capabilities, organizing our marketing team, and dedicated business development efforts, and we expect future periods to continue to improve.”  

Financial highlights:

·       BioLargo achieved record company-wide revenue. Revenues for the period ended September 30, 2020 were approximately $650,000, representing about a 60% increase compared to the $418,000 generated in the second quarter of 2020.  Revenues for the nine months ended September 30, 2020 were approximately $1,600,000, about a 20% increase compared to the $1,324,000 generated in the nine months ended September 30, 2019.

·       Substantial improvements to the company’s balance sheet, with $3,553,000 of debt being converted to equity by the company since December 31, 2019.

Highlights for BioLargo’s subsidiaries:

Clyra Medical Technologies

·       Clyra is executing on its comprehensive roll out plan for Clyraguard Personal Protective Spray, having overcome early challenges developing a robust manufacturing and supply chain during Covid. New manufacturing relationships support capacity of up to 1,000,000 Clyraguard units per month, and ample supply has been placed with distributors across the country.

·       Sales channels launching now include the largest distributors to the healthcare and restaurant industries, Amazon.com, a revamped Clyraguard website (www.Clyraguard.com), and multiple online resellers, with a retail unit price of $25 per bottle.

·       The Clyraguard launch is supported by new company additions – Shawn Dougherty (Mophie founder), Johnny Sirpilla (former President of Camping World), and new agreements with a national marketing and public relations firm, and national sales organization, to be announced soon.

BioLargo Engineering, Science & Technologies

·       Multiple projects are being finalized with two major municipal public water agencies for the company’s PFAS treatment technology (the BioLargo AEC).

·       Developed a proprietary and patent-pending process to extract valuable mineral resources from a large industrial waste site. As a consequence of this new process, a client is planning a substantial long-term project expected to generate over $1B in revenues for the project. As the client’s engineering services provider, and developer of the technology, BioLargo Engineering is in discussions with the client to secure its role as the project manager and/or lead engineer.

·       Secured a client contract for a project to use regenerative thermal oxidation for air quality control (a particular expertise of some of our engineers), which is expected to generate $500,000 in revenue for BioLargo Engineering through 2021.  

·       BioLargo Engineering now has contracts in place for approximately $1,000,000 in revenue, which is expected to be realized between now through the end of 2021.

ONM Environmental

·       Revenues in the third quarter of 2020 began to rebound from their pandemic-related dip to approximately $350,000.

·       With nearly $400,000 in construction business already secured for the fourth quarter of 2020,  management expects the fourth quarter 2020 to be a new high record for revenue at ONM Environmental.

·       Cannabusters (ONM Environmental’s white label partner for the cannabis industry) is gaining traction in the market, resulting in 12 equipment installations for ONM Environmental so far, with another three contracted for the fourth quarter 2020.

BioLargo Water

·       BioLargo Water’s first commercial project for its AOS water treatment technology, wherein the first for-profit installation of an AOS will take place at a poultry farm, is moving forward as planned, and which is expected to generate more than $500,000 in revenue over the next year.

·       Our engineers are building the AOS unit to be installed at the wastewater treatment facility near Montreal, Quebec, for the demonstration pilot to be run in partnership with acclaimed water experts at the Centre des Technologies de L’Eau (CTE).

·       BioLargo Water secured Health Canada approval for two hand sanitizer product formulations and a license to manufacture and sell these products (one of which incorporates CupriDyne technology), to serve its local community.  

·       Developed and executed crucial EPA-approved protocols to produce data to support the efficacy of a CupriDyne technology-related disinfectant in preparation for an EPA application for a hard-surface disinfectant and sanitizer, in support of BioLargo’s efforts to secure EPA registration.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.